Palbociclib
- TRADE NAME: Ibrance (Pfizer)
- INDICATIONS: Treatment of postmenopausal women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (in combination with letrozole)
- CLASS: Cyclin-dependent kinase (CDK) 4/6 inhibitor
- HALF-LIFE: 29 hours
FDA APPROVAL DATE: 02/03/2015
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Bosentan, Carbamazepine, Clarithromycin, Efavirenz, Etravirine, Grapefruit Juice, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Modafinil, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Telaprevir, Telithromycin, Verapamil, Voriconazole
PREGNANCY CATEGORY: N/A
Can cause fetal harm
Please login to see the rest of this drug profile
SKIN.
HAIR.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of palbociclib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 01/03/2024
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric